FDA Official Grilled on Delays in Over-the-Counter Drug Approvals

FDA's OTC Drug Monograph Process

• 💡 The AMUFA law was intended to increase FDA efficiency in updating OTC drug monographs and streamline market entry for innovative products.
• 🎯 Despite the law's goals, there have been few sponsor-initiated OTC monograph changes in the five years since its signing.

Implementation and Lag Time

• ⏳ Dr. Jacqueline Corrigan-Curay, Acting Director of CDER, acknowledges a lag in building the program from scratch, comparing it to PDUFA.
• 🚀 She notes that innovation and meeting goals typically begin in year three, with the expectation of seeing more updates and innovation in the future.
• 🗓️ The FDA has updated sunscreen monographs and safety labeling for acetaminophen and phenylphrine, but these are few examples over five years.

Data Requirements and Flexibility

• 🔬 The FDA emphasizes the need for rigorous data to ensure the safety and effectiveness of OTC products, as they are accessible without a healthcare provider.
• ⚖️ While the standard for safety and effectiveness is stringent, the FDA believes there is flexibility in how companies can meet these standards, including exploring alternative testing methods.
• ❓ A key concern raised is whether the volume of data required becomes a barrier, leading to excessive bureaucracy and delays.

Moving Forward

• 🤝 The FDA is committed to working with companies, clarifying data needs, and providing more opportunities for interaction.
• 🗣️ In AMUFA 2, the FDA plans to expand meetings, review protocol synopses, and offer more education on grace standards.
• ❓ A follow-up is requested to understand what specific actions the FDA will take to fulfill the original vision of the AMUFA law.